glp-1 agonist and dpp-4 inhibitor Receptor Agonists Have better Outcomes Than DPP4 Inhibitors in T2D patients & CKD Dipeptidyl peptidase 4 inhibitors in
Description
doi: 10.3389/fimmu.2021.714177 [DOI] [PMC free article] [PubMed] [Google Scholar] 7
These market segments reflect the increasing specialization of GLP-1 receptor agonists, enabling tailored treatments that improve patient outcomes
Most GLP-1 agonists are available as injections
These results far exceed the modest weight changes typically seen with lifestyle intervention alone
